Article(id=1329367120594449397, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367096166822579, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2025.01.003, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1709913600000, receivedDateStr=2024-03-09, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794875419996, onlineDateStr=2026-11-17, pubDate=1736438400000, pubDateStr=2025-01-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794875419996, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794875419996, creator=13701087609, updateTime=1794875419996, updator=13701087609, issue=Issue{id=1329367096166822579, tenantId=1146029695717560320, journalId=1319690259887390882, year='2025', volume='56', issue='1', pageStart='1', pageEnd='141', issueExtLink='null', onlineDate='null', pubDate='1736438400000', pubDateStr='2025-01-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794875414171, creator='13701087609', updateTime=1794887002143, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329415700000649272, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367096166822579, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329415700000649273, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367096166822579, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=38, endPage=46, ext={EN=ArticleExt(id=1329367120804164598, articleId=1329367120594449397, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Advance in Target Occupancy Evaluation Methods for Bruton’s Tyrosine Kinase Inhibitors, columnId=1327671169563603616, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Perspectives, runingTitle=null, highlight=null, articleAbstract=

Bruton’s tyrosine kinase(BTK) plays a crucial role in the development, proliferation, differentiation,activation and cytokine secretion of B cells. BTK inhibitors(BTKIs) can effectively block downstream cell signaling and receptor activation by blocking BTK or inhibiting its activity, and produce negative feedback on upstream signaling molecules related to the occurrence and development of various diseases, so as to playing a therapeutic role. In the research and development of BTKIs, the target occupancy, serving as an evaluation indicator of the binding affinity of drugs to BTK,has become an important pharmacodynamic parameter in preclinical and clinical studies. Besides, it not only reflects the relationship between dose and target occupancy, but also has important significance for establishing the relationship between efficacy and target occupancy. This paper reviews the evaluation methods of BTKI target occupancy, and discusses the advantages and disadvantages of these methods, aiming to provide some references for selecting suitable target occupancy evaluation methods in the research and development process of BTKI.

, authors=Yifan HUO1, 2, Dan LIU2, Suqin MAN2, Yunliang QIU2, *, authorsList=Yifan HUO, Dan LIU, Suqin MAN, Yunliang QIU, authorCompany=null, correspAuthors=Yunliang QIU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329367121127126007, articleId=1329367120594449397, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=布鲁顿酪氨酸激酶抑制剂靶点占有率评价方法的研究进展, columnId=1327671169823650466, journalTitle=中国医药工业杂志, columnName=专论, runingTitle=null, highlight=null, articleAbstract=

布鲁顿酪氨酸激酶(BTK)在B细胞的发育、增殖、分化、活化和细胞因子分泌等方面发挥着关键作用。BTK抑制剂(BTKI)通过阻断BTK或抑制其活性而有效阻断下游细胞信号转导和受体活化,并对与多种疾病发生、发展相关的上游信号分子产生负反馈作用,以发挥治疗作用。在BTKI的研发过程中,靶点占有率作为衡量药物与BTK结合能力的指标,已成为临床前和临床研究中药效学评价的重要参数,不仅可以反映给药剂量与靶点占有率之间的关系,对于建立药效与靶点占有率之间的联系也有重要意义。文章对BTKI靶点占有率的评价方法进行综述,并讨论不同方法的优缺点,以期为BTKI研发过程中选择合适的靶点占有率评价方法提供参考。

, authors=霍一凡1, 2, 刘丹2, 满素勤2, 邱云良2, *, authorsList=霍一凡, 刘丹, 满素勤, 邱云良, authorCompany=null, correspAuthors=邱云良, authorNote=

霍一凡(1995—),女,硕士,从事临床前/临床生物标志物的分析和研究。

, correspAuthorsNote=
邱云良(1978—),男,研究员,博士生导师,从事药物毒理学、生物标志物及非临床依赖性的研究。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=kabyiWAG/Jl9lXuHoYQSqQ==, magXml=KQOWZr8NL7Em9+7wbpEc9w==, pdfUrl=null, pdf=+LWGaOKYmtVccBmS9m05TQ==, pdfFileSize=1588743, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=nUW4Fdpo/e1QtD4r54cpfg==, mapNumber=null, fund=null)}, authors=[Author(id=1329367121504613375, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367121588498433, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121504613375, language=EN, stringName=Yifan HUO, firstName=Yifan, middleName=null, lastName=HUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203
2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367121689161730, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121504613375, language=CN, stringName=霍一凡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国医药工业研究总院有限公司,上海 201203
2.上海益诺思生物技术股份有限公司,上海 201203, bio={"content":"

霍一凡(1995—),女,硕士,从事临床前/临床生物标志物的分析和研究。

"}, bioImg=null, bioContent=

霍一凡(1995—),女,硕士,从事临床前/临床生物标志物的分析和研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367121328452600, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=1., ext=[AuthorCompanyExt(id=1329367121336841209, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121328452600, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121345229818, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121328452600, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院有限公司,上海 201203)]), AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])]), Author(id=1329367121756270596, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367121844350982, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121756270596, language=EN, stringName=Dan LIU, firstName=Dan, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367121911459847, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121756270596, language=CN, stringName=刘丹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益诺思生物技术股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])]), Author(id=1329367121978568713, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367122054066187, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121978568713, language=EN, stringName=Suqin MAN, firstName=Suqin, middleName=null, lastName=MAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367122116980748, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121978568713, language=CN, stringName=满素勤, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益诺思生物技术股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])]), Author(id=1329367122179895310, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=ylqiu@innostar.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329367122247004176, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367122179895310, language=EN, stringName=Yunliang QIU, firstName=Yunliang, middleName=null, lastName=QIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367122326695953, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367122179895310, language=CN, stringName=邱云良, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海益诺思生物技术股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])])], keywords=[Keyword(id=1329367122418970642, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=EN, orderNo=1, keyword=Bruton’s tyrosine kinase(BTK)), Keyword(id=1329367122477690899, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=EN, orderNo=2, keyword=BTK inhibitor), Keyword(id=1329367122536411156, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=EN, orderNo=3, keyword=signal transduction), Keyword(id=1329367122595131413, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=EN, orderNo=4, keyword=target occupancy), Keyword(id=1329367122662240278, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=EN, orderNo=5, keyword=research progress), Keyword(id=1329367122729349143, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=CN, orderNo=1, keyword=布鲁顿酪氨酸激酶(BTK)), Keyword(id=1329367122788069400, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=CN, orderNo=2, keyword=BTK抑制剂), Keyword(id=1329367122855178265, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=CN, orderNo=3, keyword=信号转导), Keyword(id=1329367122918092826, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=CN, orderNo=4, keyword=靶点占有率), Keyword(id=1329367122993590299, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, language=CN, orderNo=5, keyword=研究进展)], refs=[Reference(id=1329367123173945373, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=MCDONALD C, XANTHOPOULOS C, KOSTARELI E.The role of Bruton’s tyrosine kinase in the immune system and disease [J].Immunology, 2021, 164(4): 722-736., articleTitle=null, refAbstract=null), Reference(id=1329367123236859934, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=BROW R E.Hematology: basic principles and practice.5e[Book Review] [J].Aust J Med Sci, 2009, 30(3): 105-106., articleTitle=null, refAbstract=null), Reference(id=1329367123291385887, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=LIANG C Y, TIAN D N, REN X D, et al.The development of Bruton’s tyrosine kinase(BTK) inhibitors from 2012 to 2017: a mini-review [J].Eur J Med Chem, 2018, 151: 315-326., articleTitle=null, refAbstract=null), Reference(id=1329367123362689056, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=GOESS C, HARRIS C M, MURDOCK S, et al.ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation [J].Mod Rheumatol, 2018, 29(3): 510-512., articleTitle=null, refAbstract=null), Reference(id=1329367123484323873, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=PULZ R, ANGST D, DAWSON J, et al.Design of potent and selective covalent inhibitors of Bruton’s tyrosine kinase targeting an inactive conformation [J].ACS Med Chem Lett,2019, 10(10): 1467-1472., articleTitle=null, refAbstract=null), Reference(id=1329367123543044130, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=HENDRIKS R W, YUVARAJ S, KIL L P.Targeting Bruton’s tyrosine kinase in B cell malignancies [J].Nat Rev Cancer, 2014, 14(4): 219-232., articleTitle=null, refAbstract=null), Reference(id=1329367123601764387, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=HASELMAYER P, CAMPS M, LIU-BUJALSKI L, et al.Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models [J].J Immunol,2019, 202(10): 2888-2906., articleTitle=null, refAbstract=null), Reference(id=1329367123668873252, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=CATLETT I M, NOWAK M, KUNDU S, et al.Safety,pharmacokinetics and pharmacodynamics of branebrutinib(BMS-986195), a covalent, irreversible inhibitor of Bruton’s tyrosine kinase: randomised phaseⅠ, placebo-controlled trial in healthy participants [J].Br J Clin Pharmacol, 2020,86(9): 1849-1859., articleTitle=null, refAbstract=null), Reference(id=1329367123740176421, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=BECKER A, MARTIN E C, MITCHELL D Y, et al.Safety, tolerability, pharmacokinetics, target occupancy, and concentration-QT analysis of the novel BTK inhibitor evobrutinib in healthy volunteers [J].Clin Transl Sci, 2020,13(2): 325-336., articleTitle=null, refAbstract=null), Reference(id=1329367123798896678, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=SMITH C I, ISLAM T C, MATTSSON P T, et al.The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx,Itk, Tec, Txk and homologs in other species [J].BioEssays,2001, 23(5): 436-446., articleTitle=null, refAbstract=null), Reference(id=1329367123866005543, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=BARF T, COVEY T, IZUM R, et al.Acalabrutinib(ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile [J].J Pharmacol Exp Ther, 2017, 363(2): 240-252., articleTitle=null, refAbstract=null), Reference(id=1329367123928920104, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=LEMERY S J, ZHANG J, ROTHMANN M D, et al.U.S.Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab [J].Clin Cancer Res, 2010, 16(17): 4331-4338., articleTitle=null, refAbstract=null), Reference(id=1329367123991834665, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=SAKUMA C, SATO M, TAKENOUCHI T, et al.Specific binding of the WASP N-terminal domain to Btk is critical for TLR2 signaling in macrophages [J].Mol Immunol, 2015,63(2): 328-336., articleTitle=null, refAbstract=null), Reference(id=1329367124050554922, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=SUN C, NIERMAN P, KENDALL E K, et al.Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib [J].Blood, 2020,136(1): 93-105., articleTitle=null, refAbstract=null), Reference(id=1329367124121858091, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=HANSEN R, FIRDAUS S J, LI S W, et al.An internally controlled quantitative target occupancy assay for covalent inhibitors [J].Sci Rep, 2018, 8(1): 14312., articleTitle=null, refAbstract=null), Reference(id=1329367124197355564, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=BUNNAGE M E, CHEKLER E L P, JONES L H.Target validation using chemical probes [J].Nat Chem Biol, 2013,9(4): 195-199., articleTitle=null, refAbstract=null), Reference(id=1329367124264464429, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=BUNNAGE M E, GILBERT A M, JONES L H, et al.Know your target, know your molecule [J].Nat Chem Biol,2015, 11(6): 368-372., articleTitle=null, refAbstract=null), Reference(id=1329367124335767598, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=WEN T Y, WANG J S, SHI Y K, et al.Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances [J].Leukemia, 2021, 35(2): 312-332., articleTitle=null, refAbstract=null), Reference(id=1329367124415459375, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=BRADSHAW J M.The Src, Syk, and Tec family kinases:distinct types of molecular switches [J].Cell Signal, 2010,22(8): 1175-1184., articleTitle=null, refAbstract=null), Reference(id=1329367124478373936, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=MOHAMED A J, YU L, BÄCKESJÖ C M, et al.Bruton’s tyrosine kinase(BTK): function, regulation, and transformation with special emphasis on the PH domain [J].Immunol Rev, 2009, 228(1): 58-73., articleTitle=null, refAbstract=null), Reference(id=1329367124541288497, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=HONIGBERG L A, SMITH A M, SIRISAWAD M, et al.The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy [J].Proc Natl Acad Sci U S A, 2010,107(29): 13075-13080., articleTitle=null, refAbstract=null), Reference(id=1329367124600008754, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG X J, BARBOSA J, BLOMGREN P, et al.Discovery of potent and selective tricyclic inhibitors of Bruton’s tyrosine kinase with improved drug-like properties [J].ACS Med Chem Lett, 2017, 8(6): 608-613., articleTitle=null, refAbstract=null), Reference(id=1329367124662923315, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM M K, PAN X Q, HUANG Z Y, et al.Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis [J].Clin Immunol, 2001, 98(1): 125-132., articleTitle=null, refAbstract=null), Reference(id=1329367124725837876, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=SATTERTHWAITE A B, CEROUTRE H, KHAN W N,et al.Btk dosage determines sensitivity to B cell antigen receptor cross-linking [J].Proc Natl Acad Sci U S A, 1997,94(24): 13152-13157., articleTitle=null, refAbstract=null), Reference(id=1329367124788752437, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=QIU Y, KUNG H J.Signaling network of the Btk family kinases [J].Oncogene, 2000, 19(49): 5651-5661., articleTitle=null, refAbstract=null), Reference(id=1329367124868444214, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=MARCOTTE D J, LIU Y T, ARDUINI R M, et al.Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases [J].Protein Sci, 2010, 19(3): 429-439., articleTitle=null, refAbstract=null), Reference(id=1329367124931358775, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=VALLA K, FLOWERS C R, KOFF J L.Targeting the B cell receptor pathway in non-Hodgkin lymphoma [J].Expert Opin Investig Drugs, 2018, 27(6): 513-522., articleTitle=null, refAbstract=null), Reference(id=1329367125006856248, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=PAL SINGH S, DAMMEIJER F, HENDRIKS R W.Role of Bruton’s tyrosine kinase in B cells and malignancies [J].Mol Cancer, 2018, 17(1): 57., articleTitle=null, refAbstract=null), Reference(id=1329367125065576505, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=JONGSTRA-BILEN J, PUIG CANO A, HASIJA M, et al.Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis [J].J Immunol, 2008, 181(1): 288-298., articleTitle=null, refAbstract=null), Reference(id=1329367125128491066, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=SINGH J, PETTER R C, BAILLIE T A, et al.The resurgence of covalent drugs [J].Nat Rev Drug Discov,2011, 10(4): 307-317., articleTitle=null, refAbstract=null), Reference(id=1329367125183017019, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=JOHNSON A R, KOHLI P B, KATEWA A, et al.Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations [J].ACS Chem Biol, 2016, 11(10): 2897-2907., articleTitle=null, refAbstract=null), Reference(id=1329367125250125884, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=BOND D A, WOYACH J A.Targeting BTK in CLL:beyond ibrutinib [J].Curr Hematol Malig Rep, 2019, 14(3):197-205., articleTitle=null, refAbstract=null), Reference(id=1329367125325623357, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=HILLMEN P, BROWN J R, EICHHORST B F, et al.ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma[J].Future Oncol, 2020, 16(10): 517-523., articleTitle=null, refAbstract=null), Reference(id=1329367125396926526, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=YU H, TRUONG H, MITCHELL S A, et al.Homogeneous BTK occupancy assay for pharmacodynamic assessment of tirabrutinib(GS-4059/ONO-4059) target engagement [J].SLAS Discov, 2018, 23(9): 919-929., articleTitle=null, refAbstract=null), Reference(id=1329367125476618303, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=AKINLEYE A, CHEN Y, MUKHI N, et al.Ibrutinib and novel BTK inhibitors in clinical development [J].J Hematol Oncol, 2013, 6(1): 59., articleTitle=null, refAbstract=null), Reference(id=1329367125526949952, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=THOMPSON P A, TAM C S.Pirtobrutinib: a new hope for patients with BTK-inhibitor refractory lymphoproliferative disorders [J].Blood, 2023, 141(26): 3137-3142., articleTitle=null, refAbstract=null), Reference(id=1329367125594058817, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=GOMEZ E B, EBATA K, RANDERIA H S, et al.Pirtobrutinib preclinical characterization: a highly selective, non-covalent(reversible) BTK inhibitor [J].Blood, 2023, 142(1): 62-72., articleTitle=null, refAbstract=null), Reference(id=1329367125665361986, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=ADVANI R H, BUGGY J J, SHARMAN J P, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies[J].J Clin Oncol, 2013, 31(1): 88-94., articleTitle=null, refAbstract=null), Reference(id=1329367125749248067, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=TAM C S, TROTMAN J, OPAT S, et al.Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL [J].Blood, 2019,134(11): 851-859., articleTitle=null, refAbstract=null), Reference(id=1329367125824745540, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=EVANS E K, TESTER R, ASLANIAN S, et al.Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans [J].J Pharmacol Exp Ther, 2013, 346(2): 219-228., articleTitle=null, refAbstract=null), Reference(id=1329367125908631621, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=ALSADHAN A, CHEUNG J, GULRAJANI M, et al.Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib [J].Clin Cancer Res, 2020, 26(12): 2800-2809., articleTitle=null, refAbstract=null), Reference(id=1329367125975740486, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=DURHAM T B, BLANCO M J.Target engagement in lead generation [J].Bioorg Med Chem Lett, 2015, 25(5): 998-1008., articleTitle=null, refAbstract=null), Reference(id=1329367126042849351, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=MACGLASHAN D Jr, HONIGBERG L A, SMITH A, et al.Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton’s tyrosine kinase, Btk,inhibitor [J].Int Immunopharmacol, 2011, 11(4): 475-479., articleTitle=null, refAbstract=null), Reference(id=1329367126122541128, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=SMITH P F, KRISHNARAJAH J, NUNN P A, et al.A phaseⅠ trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers [J].Br J Clin Pharmocol, 2017, 83(11): 2367-2376., articleTitle=null, refAbstract=null), Reference(id=1329367126185455689, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHENG N Y, CATLETT I M, TAYLOR K, et al.Determination of real time in vivo drug receptor occupancy for a covalent binding drug as a clinical pharmacodynamic biomarker by immunocapture-LC-MS/MS [J].Anal Chem, 2019, 91(13):8443-8452., articleTitle=null, refAbstract=null), Reference(id=1329367126256758858, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=ONG L L, VASTA J D, MONEREAU L, et al.A high-throughput BRET cellular target engagement assay links biochemical to cellular activity for Bruton’s tyrosine kinase [J].SLAS Discov, 2020, 25(2): 176-185., articleTitle=null, refAbstract=null), Reference(id=1329367126336450635, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=STEVENSON L, GAROFOLO F, DESILVA B, et al.2013 White Paper on recent issues in bioanalysis: ‘hybrid’-the best of LBA and LCMS [J].Bioanalysis, 2013, 5(23): 2903-2918., articleTitle=null, refAbstract=null), Reference(id=1329367126390976588, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=NEUBERT H, PALANDRA J, FERNÁNDEZ OCAÑA M.Quantification of biotherapeutic targets: new opportunities with immunoaffinity LC-MS/MS [J].Bioanalysis, 2014,6(13): 1731-1733., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329367123081670684, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, awardId=17DZ2252900, language=CN, fundingSource=上海市科委工程技术研究中心专项项目(17DZ2252900), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329367121328452600, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=1., ext=[AuthorCompanyExt(id=1329367121336841209, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121328452600, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121345229818, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121328452600, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院有限公司,上海 201203)]), AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2025.01.003, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2025.01.003, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2025.01.003, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2025.01.003, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1736438400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
布鲁顿酪氨酸激酶抑制剂靶点占有率评价方法的研究进展
霍一凡 1, 2 , 刘丹 2 , 满素勤 2 , 邱云良 2, *
中国医药工业杂志 | 专论 2025,56(1): 38-46
收起
收藏切换
中国医药工业杂志 |专论 2025 , 56 (1) : 38 -46
布鲁顿酪氨酸激酶抑制剂靶点占有率评价方法的研究进展
全屏
[Author(id=1329367121504613375, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367121588498433, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121504613375, language=EN, stringName=Yifan HUO, firstName=Yifan, middleName=null, lastName=HUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203
2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367121689161730, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121504613375, language=CN, stringName=霍一凡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国医药工业研究总院有限公司,上海 201203
2.上海益诺思生物技术股份有限公司,上海 201203, bio={"content":"

霍一凡(1995—),女,硕士,从事临床前/临床生物标志物的分析和研究。

"}, bioImg=null, bioContent=

霍一凡(1995—),女,硕士,从事临床前/临床生物标志物的分析和研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367121328452600, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=1., ext=[AuthorCompanyExt(id=1329367121336841209, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121328452600, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121345229818, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121328452600, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国医药工业研究总院有限公司,上海 201203)]), AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])]), Author(id=1329367121756270596, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367121844350982, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121756270596, language=EN, stringName=Dan LIU, firstName=Dan, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367121911459847, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121756270596, language=CN, stringName=刘丹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益诺思生物技术股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])]), Author(id=1329367121978568713, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367122054066187, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121978568713, language=EN, stringName=Suqin MAN, firstName=Suqin, middleName=null, lastName=MAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367122116980748, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367121978568713, language=CN, stringName=满素勤, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海益诺思生物技术股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])]), Author(id=1329367122179895310, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=ylqiu@innostar.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329367122247004176, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367122179895310, language=EN, stringName=Yunliang QIU, firstName=Yunliang, middleName=null, lastName=QIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367122326695953, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, authorId=1329367122179895310, language=CN, stringName=邱云良, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海益诺思生物技术股份有限公司,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367121420727291, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, xref=2., ext=[AuthorCompanyExt(id=1329367121429115900, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203), AuthorCompanyExt(id=1329367121437504509, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367120594449397, companyId=1329367121420727291, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海益诺思生物技术股份有限公司,上海 201203)])])]
霍一凡1, 2, 刘丹2, 满素勤2, 邱云良2, *
作者信息
  • 1.中国医药工业研究总院有限公司,上海 201203
  • 2.上海益诺思生物技术股份有限公司,上海 201203
通讯作者:
邱云良(1978—),男,研究员,博士生导师,从事药物毒理学、生物标志物及非临床依赖性的研究。E-mail:
作者简介:

霍一凡(1995—),女,硕士,从事临床前/临床生物标志物的分析和研究。

Advance in Target Occupancy Evaluation Methods for Bruton’s Tyrosine Kinase Inhibitors
Yifan HUO1, 2, Dan LIU2, Suqin MAN2, Yunliang QIU2, *
Affiliations
  • 1.China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203
  • 2.Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 201203
出版时间: 2025-01-10 doi: 10.16522/j.cnki.cjph.2025.01.003
文章导航
收藏切换

布鲁顿酪氨酸激酶(BTK)在B细胞的发育、增殖、分化、活化和细胞因子分泌等方面发挥着关键作用。BTK抑制剂(BTKI)通过阻断BTK或抑制其活性而有效阻断下游细胞信号转导和受体活化,并对与多种疾病发生、发展相关的上游信号分子产生负反馈作用,以发挥治疗作用。在BTKI的研发过程中,靶点占有率作为衡量药物与BTK结合能力的指标,已成为临床前和临床研究中药效学评价的重要参数,不仅可以反映给药剂量与靶点占有率之间的关系,对于建立药效与靶点占有率之间的联系也有重要意义。文章对BTKI靶点占有率的评价方法进行综述,并讨论不同方法的优缺点,以期为BTKI研发过程中选择合适的靶点占有率评价方法提供参考。

布鲁顿酪氨酸激酶(BTK)  /  BTK抑制剂  /  信号转导  /  靶点占有率  /  研究进展

Bruton’s tyrosine kinase(BTK) plays a crucial role in the development, proliferation, differentiation,activation and cytokine secretion of B cells. BTK inhibitors(BTKIs) can effectively block downstream cell signaling and receptor activation by blocking BTK or inhibiting its activity, and produce negative feedback on upstream signaling molecules related to the occurrence and development of various diseases, so as to playing a therapeutic role. In the research and development of BTKIs, the target occupancy, serving as an evaluation indicator of the binding affinity of drugs to BTK,has become an important pharmacodynamic parameter in preclinical and clinical studies. Besides, it not only reflects the relationship between dose and target occupancy, but also has important significance for establishing the relationship between efficacy and target occupancy. This paper reviews the evaluation methods of BTKI target occupancy, and discusses the advantages and disadvantages of these methods, aiming to provide some references for selecting suitable target occupancy evaluation methods in the research and development process of BTKI.

Bruton’s tyrosine kinase(BTK)  /  BTK inhibitor  /  signal transduction  /  target occupancy  /  research progress
霍一凡, 刘丹, 满素勤, 邱云良. 布鲁顿酪氨酸激酶抑制剂靶点占有率评价方法的研究进展. 中国医药工业杂志, 2025 , 56 (1) : 38 -46 . DOI: 10.16522/j.cnki.cjph.2025.01.003
Yifan HUO, Dan LIU, Suqin MAN, Yunliang QIU. Advance in Target Occupancy Evaluation Methods for Bruton’s Tyrosine Kinase Inhibitors[J]. Chinese Journal of Pharmaceuticals, 2025 , 56 (1) : 38 -46 . DOI: 10.16522/j.cnki.cjph.2025.01.003
  • 上海市科委工程技术研究中心专项项目(17DZ2252900)
参考文献 引证文献
排序方式:
[1]
MCDONALD C, XANTHOPOULOS C, KOSTARELI E.The role of Bruton’s tyrosine kinase in the immune system and disease [J].Immunology, 2021, 164(4): 722-736.
[2]
BROW R E.Hematology: basic principles and practice.5e[Book Review] [J].Aust J Med Sci, 2009, 30(3): 105-106.
[3]
LIANG C Y, TIAN D N, REN X D, et al.The development of Bruton’s tyrosine kinase(BTK) inhibitors from 2012 to 2017: a mini-review [J].Eur J Med Chem, 2018, 151: 315-326.
[4]
GOESS C, HARRIS C M, MURDOCK S, et al.ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation [J].Mod Rheumatol, 2018, 29(3): 510-512.
[5]
PULZ R, ANGST D, DAWSON J, et al.Design of potent and selective covalent inhibitors of Bruton’s tyrosine kinase targeting an inactive conformation [J].ACS Med Chem Lett,2019, 10(10): 1467-1472.
[6]
HENDRIKS R W, YUVARAJ S, KIL L P.Targeting Bruton’s tyrosine kinase in B cell malignancies [J].Nat Rev Cancer, 2014, 14(4): 219-232.
[7]
HASELMAYER P, CAMPS M, LIU-BUJALSKI L, et al.Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models [J].J Immunol,2019, 202(10): 2888-2906.
[8]
CATLETT I M, NOWAK M, KUNDU S, et al.Safety,pharmacokinetics and pharmacodynamics of branebrutinib(BMS-986195), a covalent, irreversible inhibitor of Bruton’s tyrosine kinase: randomised phaseⅠ, placebo-controlled trial in healthy participants [J].Br J Clin Pharmacol, 2020,86(9): 1849-1859.
[9]
BECKER A, MARTIN E C, MITCHELL D Y, et al.Safety, tolerability, pharmacokinetics, target occupancy, and concentration-QT analysis of the novel BTK inhibitor evobrutinib in healthy volunteers [J].Clin Transl Sci, 2020,13(2): 325-336.
[10]
SMITH C I, ISLAM T C, MATTSSON P T, et al.The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx,Itk, Tec, Txk and homologs in other species [J].BioEssays,2001, 23(5): 436-446.
[11]
BARF T, COVEY T, IZUM R, et al.Acalabrutinib(ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile [J].J Pharmacol Exp Ther, 2017, 363(2): 240-252.
[12]
LEMERY S J, ZHANG J, ROTHMANN M D, et al.U.S.Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab [J].Clin Cancer Res, 2010, 16(17): 4331-4338.
[13]
SAKUMA C, SATO M, TAKENOUCHI T, et al.Specific binding of the WASP N-terminal domain to Btk is critical for TLR2 signaling in macrophages [J].Mol Immunol, 2015,63(2): 328-336.
[14]
SUN C, NIERMAN P, KENDALL E K, et al.Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib [J].Blood, 2020,136(1): 93-105.
[15]
HANSEN R, FIRDAUS S J, LI S W, et al.An internally controlled quantitative target occupancy assay for covalent inhibitors [J].Sci Rep, 2018, 8(1): 14312.
[16]
BUNNAGE M E, CHEKLER E L P, JONES L H.Target validation using chemical probes [J].Nat Chem Biol, 2013,9(4): 195-199.
[17]
BUNNAGE M E, GILBERT A M, JONES L H, et al.Know your target, know your molecule [J].Nat Chem Biol,2015, 11(6): 368-372.
[18]
WEN T Y, WANG J S, SHI Y K, et al.Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances [J].Leukemia, 2021, 35(2): 312-332.
[19]
BRADSHAW J M.The Src, Syk, and Tec family kinases:distinct types of molecular switches [J].Cell Signal, 2010,22(8): 1175-1184.
[20]
MOHAMED A J, YU L, BÄCKESJÖ C M, et al.Bruton’s tyrosine kinase(BTK): function, regulation, and transformation with special emphasis on the PH domain [J].Immunol Rev, 2009, 228(1): 58-73.
[21]
HONIGBERG L A, SMITH A M, SIRISAWAD M, et al.The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy [J].Proc Natl Acad Sci U S A, 2010,107(29): 13075-13080.
[22]
WANG X J, BARBOSA J, BLOMGREN P, et al.Discovery of potent and selective tricyclic inhibitors of Bruton’s tyrosine kinase with improved drug-like properties [J].ACS Med Chem Lett, 2017, 8(6): 608-613.
[23]
KIM M K, PAN X Q, HUANG Z Y, et al.Fc gamma receptors differ in their structural requirements for interaction with the tyrosine kinase Syk in the initial steps of signaling for phagocytosis [J].Clin Immunol, 2001, 98(1): 125-132.
[24]
SATTERTHWAITE A B, CEROUTRE H, KHAN W N,et al.Btk dosage determines sensitivity to B cell antigen receptor cross-linking [J].Proc Natl Acad Sci U S A, 1997,94(24): 13152-13157.
[25]
QIU Y, KUNG H J.Signaling network of the Btk family kinases [J].Oncogene, 2000, 19(49): 5651-5661.
[26]
MARCOTTE D J, LIU Y T, ARDUINI R M, et al.Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases [J].Protein Sci, 2010, 19(3): 429-439.
[27]
VALLA K, FLOWERS C R, KOFF J L.Targeting the B cell receptor pathway in non-Hodgkin lymphoma [J].Expert Opin Investig Drugs, 2018, 27(6): 513-522.
[28]
PAL SINGH S, DAMMEIJER F, HENDRIKS R W.Role of Bruton’s tyrosine kinase in B cells and malignancies [J].Mol Cancer, 2018, 17(1): 57.
[29]
JONGSTRA-BILEN J, PUIG CANO A, HASIJA M, et al.Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis [J].J Immunol, 2008, 181(1): 288-298.
[30]
SINGH J, PETTER R C, BAILLIE T A, et al.The resurgence of covalent drugs [J].Nat Rev Drug Discov,2011, 10(4): 307-317.
[31]
JOHNSON A R, KOHLI P B, KATEWA A, et al.Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations [J].ACS Chem Biol, 2016, 11(10): 2897-2907.
[32]
BOND D A, WOYACH J A.Targeting BTK in CLL:beyond ibrutinib [J].Curr Hematol Malig Rep, 2019, 14(3):197-205.
[33]
HILLMEN P, BROWN J R, EICHHORST B F, et al.ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma[J].Future Oncol, 2020, 16(10): 517-523.
[34]
YU H, TRUONG H, MITCHELL S A, et al.Homogeneous BTK occupancy assay for pharmacodynamic assessment of tirabrutinib(GS-4059/ONO-4059) target engagement [J].SLAS Discov, 2018, 23(9): 919-929.
[35]
AKINLEYE A, CHEN Y, MUKHI N, et al.Ibrutinib and novel BTK inhibitors in clinical development [J].J Hematol Oncol, 2013, 6(1): 59.
[36]
THOMPSON P A, TAM C S.Pirtobrutinib: a new hope for patients with BTK-inhibitor refractory lymphoproliferative disorders [J].Blood, 2023, 141(26): 3137-3142.
[37]
GOMEZ E B, EBATA K, RANDERIA H S, et al.Pirtobrutinib preclinical characterization: a highly selective, non-covalent(reversible) BTK inhibitor [J].Blood, 2023, 142(1): 62-72.
[38]
ADVANI R H, BUGGY J J, SHARMAN J P, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies[J].J Clin Oncol, 2013, 31(1): 88-94.
[39]
TAM C S, TROTMAN J, OPAT S, et al.Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL [J].Blood, 2019,134(11): 851-859.
[40]
EVANS E K, TESTER R, ASLANIAN S, et al.Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans [J].J Pharmacol Exp Ther, 2013, 346(2): 219-228.
[41]
ALSADHAN A, CHEUNG J, GULRAJANI M, et al.Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib [J].Clin Cancer Res, 2020, 26(12): 2800-2809.
[42]
DURHAM T B, BLANCO M J.Target engagement in lead generation [J].Bioorg Med Chem Lett, 2015, 25(5): 998-1008.
[43]
MACGLASHAN D Jr, HONIGBERG L A, SMITH A, et al.Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton’s tyrosine kinase, Btk,inhibitor [J].Int Immunopharmacol, 2011, 11(4): 475-479.
[44]
SMITH P F, KRISHNARAJAH J, NUNN P A, et al.A phaseⅠ trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers [J].Br J Clin Pharmocol, 2017, 83(11): 2367-2376.
[45]
ZHENG N Y, CATLETT I M, TAYLOR K, et al.Determination of real time in vivo drug receptor occupancy for a covalent binding drug as a clinical pharmacodynamic biomarker by immunocapture-LC-MS/MS [J].Anal Chem, 2019, 91(13):8443-8452.
[46]
ONG L L, VASTA J D, MONEREAU L, et al.A high-throughput BRET cellular target engagement assay links biochemical to cellular activity for Bruton’s tyrosine kinase [J].SLAS Discov, 2020, 25(2): 176-185.
[47]
STEVENSON L, GAROFOLO F, DESILVA B, et al.2013 White Paper on recent issues in bioanalysis: ‘hybrid’-the best of LBA and LCMS [J].Bioanalysis, 2013, 5(23): 2903-2918.
[48]
NEUBERT H, PALANDRA J, FERNÁNDEZ OCAÑA M.Quantification of biotherapeutic targets: new opportunities with immunoaffinity LC-MS/MS [J].Bioanalysis, 2014,6(13): 1731-1733.
2025年第56卷第1期
59
13
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2025.01.003
  • 接收时间:2024-03-09
  • 首发时间:2026-11-17
  • 出版时间:2025-01-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-03-09
基金
上海市科委工程技术研究中心专项项目(17DZ2252900)
作者信息
    1.中国医药工业研究总院有限公司,上海 201203
    2.上海益诺思生物技术股份有限公司,上海 201203

通讯作者:

邱云良(1978—),男,研究员,博士生导师,从事药物毒理学、生物标志物及非临床依赖性的研究。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2025.01.003
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏